Skip to content

RETINALGENIX TECHNOLOGIES INC.: 10-Q filed 2023-08-14

What RETINALGENIX TECHNOLOGIES INC. reported in its quarterly report filed 2023-08-14 (fiscal Q2 2023): 24 published measures, 72 facts as tagged in accession 0001493152-23-028030.

This filing

Form
10-Q (quarterly report)
Filed
2023-08-14
Fiscal period
fiscal Q2 2023
Accession
0001493152-23-028030 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All RETINALGENIX TECHNOLOGIES INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-06-302,119USD
At 2022-12-31294USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-06-301,776,950USD
At 2022-12-311,069,357USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-06-30-1,774,831USD
At 2023-03-31-1,774,831USD
At 2022-12-31-1,069,063USD
At 2022-06-30-675,175USD
At 2022-03-31-724,323USD
At 2021-12-31-464,675USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-06-301,913USD
At 2022-12-3138USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-352,143USD91
2023-01-01 to 2023-06-30-862,786USD181
2023-01-01 to 2023-03-31-510,643USD90
2022-04-01 to 2022-06-30-359,335USD91
2022-01-01 to 2022-06-30-734,534USD181
2022-01-01 to 2022-03-31-375,199USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-201,385USD181
2022-01-01 to 2022-06-30-107,106USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-06-30203,260USD181
2022-01-01 to 2022-06-30102,186USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-06-30-9,881,092USD
At 2022-12-31-9,018,306USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-04-01 to 2023-06-3017,272,116shares91
2023-01-01 to 2023-06-3017,272,116shares181
2022-04-01 to 2022-06-3014,523,114shares91
2022-01-01 to 2022-06-3014,400,037shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-04-01 to 2023-06-3017,272,116shares91
2023-01-01 to 2023-06-3017,272,116shares181
2022-04-01 to 2022-06-3014,523,114shares91
2022-01-01 to 2022-06-3014,400,037shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-0.02USD/shares91
2023-01-01 to 2023-06-30-0.05USD/shares181
2022-04-01 to 2022-06-30-0.02USD/shares91
2022-01-01 to 2022-06-30-0.05USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-0.02USD/shares91
2023-01-01 to 2023-06-30-0.05USD/shares181
2022-04-01 to 2022-06-30-0.02USD/shares91
2022-01-01 to 2022-06-30-0.05USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-06-30206USD
At 2022-12-31256USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-04-01 to 2023-06-3078,509USD91
2023-01-01 to 2023-06-30157,018USD181
2022-04-01 to 2022-06-3055,051USD91
2022-01-01 to 2022-06-30110,102USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-06-301,913USD
At 2022-12-3138USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-04-01 to 2023-06-30960USD91
2023-01-01 to 2023-06-301,920USD181
2022-04-01 to 2022-06-301,460USD91
2022-01-01 to 2022-06-302,920USD181

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-04-01 to 2023-06-30351,183USD91
2023-01-01 to 2023-06-30860,866USD181
2022-04-01 to 2022-06-30357,875USD91
2022-01-01 to 2022-06-30731,614USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-04-01 to 2023-06-30152,577USD91
2023-01-01 to 2023-06-30380,509USD181
2022-04-01 to 2022-06-30135,439USD91
2022-01-01 to 2022-06-30292,932USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-06-3017,272,116shares
At 2022-12-3117,272,116shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-06-308,104,478USD
At 2022-12-317,947,460USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2023-06-30101USD
At 2022-12-31101USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30120,097USD91
2023-01-01 to 2023-06-30323,339USD181
2022-04-01 to 2022-06-30167,385USD91
2022-01-01 to 2022-06-30328,580USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-01-01 to 2023-06-3050USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2022-01-01 to 2022-06-3060,500USD181

Inspect the source

Entity
RETINALGENIX TECHNOLOGIES INC. / CIK 0001836295
Captured
2026-09-21T17:29:46.648Z
SEC response SHA-256
dd1391ce51bf49d231e305a3aac122a3dd931e6d5a5195ef8432fe80b7fd24ad

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001836295.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))